At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 338 enrolled
Drug / intervention
dalteparindrug
Likely dose
dalteparin 200IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism
In Brief
A Phase 4 clinical trial evaluating dalteparin for Cancer. Completed, enrolled 338 participants across 42 sites in 5 countries.
Detailed Summary
The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesAustria, Canada, Netherlands, Spain, United States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJul 2009
Primary CompletionMar 2012
Study CompletionJun 2013
TodayJul 2026
First PostedJul 21, 2009
Enrollment StartJun 1, 2009
Primary CompletionMar 1, 2012
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.9 years ago
Interventions
dalteparindrug
Daily subcutaneous injection 200IU/kg dalteparin